Attenuated Salmonella vaccines against Eimeria

Project: Research project

Project Details


Attenuated Salmonella vaccines against Eimeria Attenuated Salmonella vaccines against Eimeria Elanco/ASU Eimeria Proposal Nov. 28, 2012 V2 This proposal contains proprietary information, some of which will be included in patent applications pending the outcome of additional experiments. The information in this proposal is therefore provided for the purpose of discussion with Elanco only. Introduction Avian coccidiosis is an intestinal disease caused by protozoa of the genus Eimeria. The disease is responsible for over $ 1.5 billion loss per year in the worldwide poultry industry due mainly to lower weight gain in Eimeria-infected chickens. Anti-coccidial drugs and live and attenuated parasite vaccines are the primary methods of disease control. However, the use of anti-coccidials has led to drug resistance, and live vaccines seed the poultry house with virulent oocysts. We have developed several efficient delivery systems for Eimeria protective antigens to prevent coccidiosis in poultry. Salmonella is an ideal vehicle for delivery of antigens of intracellular pathogens because it can reproduce inside host cells to synthesize and effectively deliver protective antigens within infected cells to stimulate mucosal, systemic and cellular immunities. Over the past decade, our group has improved strategies to use recombinant attenuated Salmonella vaccines (RASVs) to deliver protective antigens of pathogens such as Eimeria, Streptococcus pneumoniae, Yersinia sp., influenza, etc. RASVs were used to stimulate immune responses to Eimeria antigens via the type 3 secretion system (T3SS) and the type 2 secretion system (T2SS) of Salmonella. Also, a novel biological containment system was developed that results in programmed Salmonella cell death due to regulated vaccine cell lysis in vivo with delivery of a bolus of protective antigen to induce an efficacious immune response. Aims of the collaboration The goal is to improve and evaluate the use of RASVs to deliver Eimeria protective antigens and draws heavily on the knowledge, technical advances, and accomplishments acquired over the past several years. Phase I: to e
Effective start/end date3/22/135/31/14


  • INDUSTRY: Domestic Company: $357,491.00


Explore the research topics touched on by this project. These labels are generated based on the underlying awards/grants. Together they form a unique fingerprint.